The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
An analyst wrote that a best-case scenario for Amarin is that it may take 2-3 years for generic versions of Vascepa to hit the market. But the company has likely lost its luster as an acquisition target.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
The Food and Drug Administration just OKed biopharma company Amarin to promote its only drug, Vascepa, for off-label use.